Boston Scientific Co. (NYSE:BSX) EVP Sells $671,228.34 in Stock

Boston Scientific Co. (NYSE:BSX) EVP John Bradley Sorenson sold 6,389 shares of Boston Scientific stock in a transaction on Wednesday, February 12th. The shares were sold at an average price of $105.06, for a total value of $671,228.34. Following the completion of the sale, the executive vice president now directly owns 24,293 shares of the company’s stock, valued at approximately $2,552,222.58. This represents a 20.82 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

John Bradley Sorenson also recently made the following trade(s):

• On Friday, February 7th, John Bradley Sorenson sold 6,528 shares of Boston Scientific stock. The shares were sold at an average price of $104.97, for a total value of $685,244.16.
• On Thursday, January 2nd, John Bradley Sorenson sold 4,119 shares of Boston Scientific stock. The shares were sold at an average price of $90.02, for a total value of $370,792.38.

Boston Scientific Stock Performance

Shares of BSX opened at $106.20 on Friday. The business’s 50 day moving average is $96.44 and its two-hundred day moving average is $88.19. Boston Scientific Co. has a 52-week low of $65.33 and a 52-week high of $107.17. The firm has a market cap of $156.51 billion, a price-to-earnings ratio of 84.96, a PEG ratio of 2.79 and a beta of 0.80. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 18.11% and a net margin of 11.07%. Analysts forecast that Boston Scientific Co. will post 2.83 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on BSX shares. Mizuho boosted their price target on Boston Scientific from $100.00 to $110.00 and gave the company an “outperform” rating in a research report on Thursday, October 24th. UBS Group boosted their price target on Boston Scientific from $105.00 to $130.00 and gave the company a “buy” rating in a research report on Friday, February 7th. Citigroup boosted their price target on Boston Scientific from $107.00 to $122.00 and gave the company a “buy” rating in a research report on Thursday, February 6th. Stifel Nicolaus boosted their price target on Boston Scientific from $100.00 to $115.00 and gave the company a “buy” rating in a research report on Thursday, February 6th. Finally, Deutsche Bank Aktiengesellschaft raised Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 target price for the company in a research report on Friday, January 10th. One analyst has rated the stock with a hold rating, twenty-two have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $107.39.

Institutional Investors Weigh In On Boston Scientific

A number of institutional investors have recently made changes to their positions in BSX. Creative Planning increased its holdings in shares of Boston Scientific by 7.7% in the 3rd quarter. Creative Planning now owns 204,208 shares of the medical equipment provider’s stock valued at $17,113,000 after acquiring an additional 14,663 shares during the last quarter. NBC Securities Inc. increased its holdings in shares of Boston Scientific by 20.5% in the 3rd quarter. NBC Securities Inc. now owns 11,761 shares of the medical equipment provider’s stock valued at $985,000 after acquiring an additional 2,001 shares during the last quarter. Swedbank AB increased its holdings in shares of Boston Scientific by 0.6% in the 3rd quarter. Swedbank AB now owns 1,430,925 shares of the medical equipment provider’s stock valued at $119,912,000 after acquiring an additional 8,246 shares during the last quarter. Wolff Wiese Magana LLC increased its holdings in shares of Boston Scientific by 7,262.5% in the 3rd quarter. Wolff Wiese Magana LLC now owns 2,945 shares of the medical equipment provider’s stock valued at $247,000 after acquiring an additional 2,905 shares during the last quarter. Finally, AAFMAA Wealth Management & Trust LLC grew its stake in Boston Scientific by 10.4% during the 3rd quarter. AAFMAA Wealth Management & Trust LLC now owns 32,732 shares of the medical equipment provider’s stock worth $2,743,000 after buying an additional 3,077 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.